Influence of<i>Leishmania (Viannia)</i>Species on the Response to Antimonial Treatment in Patients with American Tegumentary Leishmaniasis

Arévalo, Jorge; Ramı́rez, Luı́s Eduardo; Adaui, Vanessa; Zimic, Mirko; Tulliano, Gianfranco; Miranda‐Verástegui, César; Lazo, María A.; Loayza‐Muro, Raúl; Doncker, Simonne De; Maurer, Anne; Chappuis, François; Dujardin, Jean‐Claude; Llanos-Cuentas, A.

doi:10.1086/518041

Cited by 228 publications

(207 citation statements)

References 25 publications

Supporting

Mentioning

190

Contrasting

Unclassified

Order By: Relevance

“…This observation was indeed pointed out in two other studies conducted in Peru where leishmania species were associated with different antimonial treatment outcomes. 10,11 This variation in cure rates has also been demonstrated in patients infected with L. ( V. ) braziliensis and L. ( V. ) guyanensis in Brazil where antimonial cure rates are lower than the ones reported in Bolivia and Peru. 9,12,13 Despite the epidemiologic importance of L. ( V. ) guyanensis in the Brazilian Amazon, only one clinical trial addressing treatment response of this leishmania species to antimonials was performed in the past 10 years.…”

Section: Introductionmentioning

confidence: 60%

Randomized Controlled Clinical Trial to Access Efficacy and Safety of Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil

Chrusciak‐Talhari¹,

Dietze²,

Talhari³

et al. 2011

The American Society of Tropical Medicine and Hygiene

141

129

View full text Add to dashboard Cite

Miltefosine has been used in the treatment of several new world cutaneous leishmaniasis (CL) species with variable efficacy. Our study is the first evidence on its clinical efficacy in Leishmania (Viannia) guyanensis. In this phase II/III randomized clinical trial, 90 CL patients were randomly allocated (2:1) to oral miltefosine (2.5 mg/kg/day/28 days) (N = 60) or parenteral antimony (15–20 mg/Sb/kg/day/20 days) (N = 30) according to age groups: 2–12 y/o and 13–65 y/o. Patients were human immunodeficiency virus (HIV) noninfected parasitological proven CL without previous treatment. Definitive cure was accessed at 6 months follow-up visit. No severe adverse events occurred. Vomiting was the most frequent adverse event (48.3%) followed by nausea (8.6%) and diarrhea (6.7%). Cure rates were 71.4% (95% confidence interval [CI] = 57.8–82.7) and 53.6% (95% CI = 33.9–72.5) (P = 0.05) for miltefosine and antimonial, respectively. There were no differences in cure rates between age groups within the same treatment arms. Miltefosine was safe and relatively well tolerated and cure rate was higher than antimony.

show abstract

Section: Introductionmentioning

confidence: 60%

Randomized Controlled Clinical Trial to Access Efficacy and Safety of Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil

Chrusciak‐Talhari¹,

Dietze²,

Talhari³

et al. 2011

The American Society of Tropical Medicine and Hygiene

141

129

View full text Add to dashboard Cite

show abstract

“…3,[15][16][17] Capture of sand flies and identification. Peridomiciliary sand fly specimens were captured in September, November, and December of 2009 (before and during the rainy season) in the vicinity of 10 arbitrarily selected houses during 10 consecutive days each month (Figure 1).…”

Section: Methodsmentioning

confidence: 99%

Natural Leishmania Infection of Lutzomyia auraensis in Madre de Dios, Peru, Detected by a Fluorescence Resonance Energy Transfer–Based Real-Time Polymerase Chain Reaction

Valdivia

Santos²,

Fernández³

et al. 2012

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Leishmania species of the Viannia subgenus are responsible for most cases of New World tegumentary leishmaniasis. However, little is known about the vectors involved in disease transmission in the Amazon regions of Peru. We used a novel real-time polymerase chain reaction (PCR) to assess Leishmania infections in phlebotomines collected in rural areas of Madre de Dios, Peru. A total of 1,299 non-blood fed female sand flies from 33 species were captured by using miniature CDC light traps. Lutzomyia auraensis was the most abundant species (63%) in this area. Seven of 164 pools were positive by PCR for Leishmania by kinetoplast DNA. The real-time PCR identified four Lu. auraensis pools as positive for L. (Viannia) lainsoni and L. (V.) braziliensis. The minimum infection prevalence for Lu. auraensis was estimated to be 0.6% (95% confidence interval = 0.20-1.42%). Further studies are needed to assess the importance of Lu. auraensis in the transmission of New World tegumentary leishmaniasis in hyperendemic areas of Peru.

show abstract

“…It has been previously demonstrated that at 12 months posttreatment, 30% of L. (V.) braziliensis-infected patients showed treatment failure with pentavalent antimony compared with 25% of L. (V.) peruviana-infected patients and 8% of L. (V.) guyanensis-infected patients, thus reiterating a species specificity to treatment response. 6 In Peru, where approximately 10,000 new cases of leishmaniasis are reported annually, 7 four species of the L.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous Infection with Leishmania (Viannia) braziliensis and L. (V.) lainsoni in a Peruvian Patient with Cutaneous Leishmaniasis

Veland

Valencia²,

Alba³

et al. 2013

The American Society of Tropical Medicine and Hygiene

Self Cite

View full text Add to dashboard Cite

show abstract

Influence ofLeishmania (Viannia)Species on the Response to Antimonial Treatment in Patients with American Tegumentary Leishmaniasis

Abstract: Leishmania species can influence SbV treatment outcome in patients with CL. Therefore, parasite identification is of utmost clinical importance, because it should lead to a species-oriented treatment.

Cited by 228 publications

References 25 publications

Randomized Controlled Clinical Trial to Access Efficacy and Safety of Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil

Randomized Controlled Clinical Trial to Access Efficacy and Safety of Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil

Natural Leishmania Infection of Lutzomyia auraensis in Madre de Dios, Peru, Detected by a Fluorescence Resonance Energy Transfer–Based Real-Time Polymerase Chain Reaction

Simultaneous Infection with Leishmania (Viannia) braziliensis and L. (V.) lainsoni in a Peruvian Patient with Cutaneous Leishmaniasis

Contact Info

Product

Resources

About